Sermorelin and NAD+ can appear in the same treatment package, but a shared package does not establish that they work better together. Sermorelin stimulates growth-hormone-related signaling; NAD+ is a coenzyme involved in cellular metabolism. Each proposed treatment needs a clear purpose, and the combination needs evidence of its own.
The sources reviewed for this guide did not establish a controlled human trial showing that adding NAD+ to sermorelin improves energy, recovery, or healthy lifespan. If a clinic proposes both, ask what additional benefit is expected, how it will be measured, and who will review new symptoms. A broad promise of cellular health does not answer those questions.
A marketed bundle is not a trial of combined treatment. NAD+ infusion research and sermorelin research cannot be added together to prove better energy, recovery, or longevity.
Separate a bundle from a combined formulation
Olympia’s public catalog lists an NAD+ and sermorelin injectable bundle. That establishes a marketed offering. It does not establish that the substances are mixed in one vial, should be placed in one syringe, or have been tested together in a clinical trial.
Ask whether you would receive separate prescriptions and containers, and obtain the instructions for each. Our Olympia review examines the catalog and the questions it leaves open. The dispensing label, rather than the bundle’s name, should identify what will actually be supplied.
A clinic may describe a package in terms of convenience or pricing. Those practical features should be considered separately from any claim that the ingredients improve one another’s effects.
What the intravenous NAD+ pilot studied
A 2019 pilot study examined changes in blood and urine NAD-related compounds during and after a six-hour intravenous NAD+ infusion. It investigated the handling of infused NAD+ and its metabolites. It was not a study of sermorelin plus NAD+.
Measurements showing what happens to a substance after infusion do not demonstrate lasting improvements in fatigue, strength, or aging. An infusion study also cannot automatically validate a different injection route or an oral NAD-related supplement. The actual preparation, route, population, and measured outcome remain part of the evidence.
Our sermorelin versus NAD+ comparison explains these distinctions. If a clinic cites an oral precursor study, ask whether the product being offered contains that precursor or NAD+ itself. The names are related, but the evidence is not interchangeable.
Product quality creates another set of questions
The FDA’s sterile-compounding alert describes concerns about unsuitable ingredients used in injectable NAD+ products. It also reports reactions including severe chills, shaking, vomiting, and fatigue, sometimes requiring medical treatment. These reports do not give a reliable event rate for every preparation.
A substance occurring naturally in the body does not establish that an injected product is sterile or appropriately prepared. Ask which pharmacy makes each prescription, who provides the administration instructions, and how a product complaint is handled. We have not independently tested products or audited a supplier.
If symptoms occur during an infusion, tell the administering professional immediately. For a home product, follow the prescribed response plan and seek urgent care when symptoms warrant it. Do not treat a significant reaction as an expected sign of a beneficial “detox.”
Combining treatments makes follow-up more complicated
When several products begin together, it becomes harder to identify which contributed to an improvement or a new problem. A treatment record should include the exact ingredients, routes, starting dates, other medication changes, and the outcome being assessed.
The peptide-stack guide explains why different mechanisms do not remove the need to evaluate a combination. Separating administration times is not proof that combined treatment is safe, and a compatible-looking solution is not evidence that products may be mixed.
Ask the prescriber what information would lead to continuing one product while reconsidering the other. A useful answer is more specific than promising that the package provides complete support.
Compare the total commitment with the intended benefit
An infusion visit, a home injection, and an oral preparation involve different costs, time, training, and follow-up. Request itemized charges over the same period. A bundle discount does not establish that both components are clinically necessary.
If fatigue is the main concern, the energy and fatigue guide helps frame the assessment before choosing a product. The cost worksheet can then make the financial commitment visible. The decision should connect an identifiable problem, relevant evidence, and a reassessment plan for each treatment.
Sources & further reading
Provider pages describe offers; they do not independently establish treatment benefits. Sources checked September 21, 2026.
This article is education, not a diagnosis, prescription, or dosing plan. Discuss treatment and alternatives with a licensed clinician who knows your history. Compounded medications are not FDA-approved.